Patents by Inventor Jonathan Gillespie

Jonathan Gillespie has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250092023
    Abstract: The present disclosure provides piperazine substituted fused azadecalin compounds of Formula J, I, Ia, Ib, Ib-1, Ib-2, Ic and Id for use in pharmaceutical formulations, and for modulating glucocorticoid receptors.
    Type: Application
    Filed: August 8, 2024
    Publication date: March 20, 2025
    Inventors: Mark Mills, Andrew William Phillips, Bohdan Waszkowycz, Hazel Joan Hunt, Angus Morrison, Angelo Pugliese, Jonathan Gillespie, Euan Fordyce
  • Patent number: 12098144
    Abstract: Provided are piperazine substituted fused azadecalin compounds of Formula J, I, Ia, Ib, Ib-1, Ib-2, Ic and Id for use in pharmaceutical formulations, and for modulating glucocorticoid receptors.
    Type: Grant
    Filed: December 20, 2022
    Date of Patent: September 24, 2024
    Assignee: Corcept Therapeutics Incorporated
    Inventors: Mark Mills, Andrew William Phillips, Bohdan Waszkowycz, Hazel Joan Hunt, Angus Morrison, Angelo Pugliese, Jonathan Gillespie, Euan Fordyce
  • Publication number: 20230192666
    Abstract: The present disclosure provides piperazine substituted fused azadecalin compounds of Formula J, I, Ia, Ib, Ib-1, Ib-2, Ic and Id for use in pharmaceutical formulations, and for modulating glucocorticoid receptors.
    Type: Application
    Filed: December 20, 2022
    Publication date: June 22, 2023
    Inventors: Mark Mills, Andrew William Phillips, Bohdan Waszkowycz, Hazel Joan Hunt, Angus Morrison, Angelo Pugliese, Jonathan Gillespie, Euan Fordyce
  • Patent number: 8633237
    Abstract: The present invention relates to anindane derivative according to formula I wherein the variables are defined as in the specification, or to a pharmaceutically acceptable salt or solvate thereof. The present invention also relates to a pharmaceutical composition comprising one or more of said indane derivatives and to their use in therapy, for instance in the treatment or prevention of psychiatric diseases where an enhancement of synaptic responses mediated by AMPA receptors is required, including schizophrenia, depression and Alzheimer's disease.
    Type: Grant
    Filed: April 8, 2010
    Date of Patent: January 21, 2014
    Assignee: Merck Sharp & Dohme B.V.
    Inventors: Kevin J. Gillen, Jonathan Gillespie, Craig Jamieson, John K. F. MacLean, Elizabeth M. Moir, Zoran Rankovic
  • Patent number: 8536214
    Abstract: The present invention relates to a heterocyclic derivative according to formula (I); wherein the variables are defined as in the specification, or to a pharmaceutically acceptable salt or solvate thereof. The present invention also relates to a pharmaceutical composition comprising said heterocyclic derivatives and to their use in therapy, for instance in the treatment or prevention of psychiatric diseases where an enhancement of synaptic responses mediated by AMPA receptors is required, including schizophrenia, depression and Alzheimer's disease.
    Type: Grant
    Filed: June 3, 2009
    Date of Patent: September 17, 2013
    Inventors: Jonathan Gillespie, Craig Jamieson, John Kinaird Fergusen MaClean, Elizabeth Margaret Moir, Zoran Rankovic
  • Patent number: 8507521
    Abstract: The present invention relates to a heterocyclic derivative of formula (I) wherein the variables are as defined in the specification, or to a pharmaceutically acceptable salt or solvate thereof. The present invention further relates to pharmaceutical compositions comprising said heterocyclic derivatives and to their use in therapy, for instance in the treatment or prevention of disorders mediated by glutamate dysfunction, such as schizophrenia and generalised anxiety disorder.
    Type: Grant
    Filed: November 2, 2010
    Date of Patent: August 13, 2013
    Assignee: Merck Sharp + Dohme B.V.
    Inventors: Julia Adam, Jonathan Gillespie, Steven Laats, John Kinnaird Ferguson MacLean, Duncan Robert McArthur
  • Publication number: 20120220622
    Abstract: The present invention relates to a heterocyclic derivative of formula (I) wherein the variables are as defined in the specification, or to a pharmaceutically acceptable salt or solvate thereof. The present invention further relates to pharmaceutical compositions comprising said heterocyclic derivatives and to their use in therapy, for instance in the treatment or prevention of disorders mediated by glutamate dysfunction, such as schizophrenia and generalised anxiety disorder.
    Type: Application
    Filed: November 2, 2010
    Publication date: August 30, 2012
    Inventors: Julia Adam, Jonathan Gillespie, Steven Laats, John Kinnaird Ferguson MacLean, Duncan Robert McArthur
  • Publication number: 20120202781
    Abstract: The present invention relates to anindane derivative according to formula I wherein the variables are defined as in the specification, or to a pharmaceutically acceptable salt or solvate thereof. The present invention also relates to a pharmaceutical composition comprising one or more of said indane derivatives and to their use in therapy, for instance in the treatment or prevention of psychiatric diseases where an enhancement of synaptic responses mediated by AMPA receptors is required, including schizophrenia, depression and Alzheimer's disease.
    Type: Application
    Filed: April 8, 2010
    Publication date: August 9, 2012
    Inventors: Kevin James Gillen, Jonathan Gillespie, Craig Jamieson, John Kinnaird Ferguson MacLean, Elizabeth Margaret Moir, Zoran Rankovic
  • Publication number: 20110092539
    Abstract: The present invention relates to a heterocyclic derivative according to formula (I); wherein the variables are defined as in the specification, or to a pharmaceutically acceptable salt or solvate thereof. The present invention also relates to a pharmaceutical composition comprising said heterocyclic derivatives and to their use in therapy, for instance in the treatment or prevention of psychiatric diseases where an enhancement of synaptic responses mediated by AMPA receptors is required, including schizophrenia, depression and Alzheimer's disease.
    Type: Application
    Filed: June 3, 2009
    Publication date: April 21, 2011
    Inventors: Jonathan Gillespie, Craig Jamieson, Zoran Rankovic
  • Patent number: 7687515
    Abstract: The present invention relates to 6-phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives having the general Formula I wherein each of the substituents is given the definition as set forth in the specification and claims, pharmaceutical compositions comprising the same as well as to the use of these derivatives for the preparation of a medicament for the treatment of cathepsin S and/or cathepsin K related diseases such as osteoporosis, atherosclerosis, inflammation and immune disorders, such as rheumatoid arthritis, and chronic pain, such as neuropathic pain.
    Type: Grant
    Filed: January 16, 2007
    Date of Patent: March 30, 2010
    Assignee: N.V. Organon
    Inventors: Jiaqiang Cai, Zoran Rankovic, Philip Stephen Jones, David Jonathan Bennett, Iain Cumming, Jonathan Gillespie
  • Publication number: 20070179138
    Abstract: The present invention relates to 6-phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives having the general Formula I wherein each of the substituents is given the definition as set forth in the specification and claims, pharmaceutical compositions comprising the same as well as to the use of these derivatives for the preparation of a medicament for the treatment of cathepsin S and/or cathepsin K related diseases such as osteoporosis, atherosclerosis, inflammation and immune disorders, such as rheumatoid arthritis, and chronic pain, such as neuropathic pain.
    Type: Application
    Filed: January 16, 2007
    Publication date: August 2, 2007
    Applicant: N.V. Organon
    Inventors: Jiaqiang Cai, Zoran Rankovic, Philip Jones, David Bennett, Iain Cumming, Jonathan Gillespie